FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139328938> ?p ?o ?g. }

• W3139328938 endingPage "610" @default.
• W3139328938 startingPage "608" @default.
• W3139328938 abstract "The heterozygous form of familial hypercholesterolemia (FH) affects about one out of 200–250 individuals or over 30 million individuals worldwide. The risk for an atherosclerotic cardiovascular event in the FH population is very high, as illustrated by the fact that, on average, only one in 5 untreated FH men reach 70 years of age. The poor prognosis of FH patients has improved with the advent of statins in the late 1980s, current life expectancy of the statin-treated FH patients being similar to that of the general population [1]. Unfortunately, however, the awareness of coronary heart disease risk factors is still insufficient among older adults [2], and, moreover, despite LDL-cholesterol lowering, older patients with FH are still at increased risk for cardiac events [3, 4].In general, the risk of patients with FH is well illustrated by their cumulative cholesterol burden (LDL-cholesterol [LDL-C] mmol/L × years) [5]. Using this metric, we can estimate that the cholesterol burden of a 70-year-old patient with FH and with an LDL-C level of 5 mmol/L is 350. Similarly, a patient with FH who has started statin therapy at the age of 30 and has reached a constant LDL-C level of 2.5 mmol/L, would have a cholesterol burden of 250 at the age of 70. The significant decrease in the burden would then translate into an improved cardiovascular prognosis.Of note, a typical statin-treated adult patient with FH has a higher cholesterol burden than a normocholesterolemic person of the same age and with a similar LDL-C level. This is because in FH patients the level of LDL-C has been significantly elevated since birth, while the diagnosis of FH and its treatment typically occurs only in middle age. Because of the high LDL-cholesterol burden, FH patients have subclinical atherosclerosis already in their thirties. Therefore, current lipid guidelines commonly advise <1.8 mmol/L as the target level of LDL-C for an adult FH patient [3]. Often, this level can be reached only by adding a proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor to the usual treatment regimen, that is, to a maximally tolerated dose of statin plus ezetimibe [3].Also, patients with FH tend to have elevated levels of serum lipoprotein(a) (Lp[a]) further increasing their risk of atherothrombotic events [6]. Accordingly, an elevated serum LDL-C level and an elevated Lp(a) level jointly promote endothelial dysfunction, which, together with the viral attack on the endothelial cells, jointly contribute to the often lethal micro- or macrothrombotic events in severe COVID-19 [7]. Regarding the myocardial damage, a recent meta-analysis revealed high numbers of acute myocardial infarction in hospitalized patients with COVID-19, the prevalence being 3.3% (95% CI, 0.3–8.5) [8].There is accumulating evidence that ongoing statin treatment is associated with lower inhospital mortality risk among COVID-19 patients (N = 8,990) [9]. In a recent meta-analysis including COVID-19 patients aged 58–75 years, the risk of death or severe disease was significantly lower with statin treatment (HR = 0.70; 95% CI 0.53–0.94). Although the studies included in this meta-analysis were retrospective and observational, the results in the different individual studies were quite consistent supporting the benefit of ongoing statin therapy in COVID-19 patients.In assessing the risk of an older patient with FH, we should also consider the age-related increase in cardiac events in patients with COVID-19. Retrospective comparison of 60–74-year old and ≥75-year old patients with COVID-19 revealed that during hospitalization acute cardiac injury was present in 1.2% and 20% in the younger and older age-group, respectively (p = 0.002) [10].Consequently, older patients with FH can be considered to be at specifically high risk of cardiac events during COVID-19. Therefore, intensifying LDL-C lowering seems vital, and, moreover, the ongoing lipid-lowering therapy should be continued during the COVID-19 [11]. The clinical benefit of a PCSK9 inhibitor was recently demonstrated in a patient population with both an elevated LDL-C and Lp(a) level, and the reduction of both lipids contributed independently to cardiovascular event reduction [12]. Therefore, patients with FH, having a life-long double risk burden, might particularly gain when a PCSK9 inhibitor is added to the conventional lipid treatment. In addition, early intervention with a PCSK9 inhibitor as an adjunct therapy has been suggested for patients with COVID-19 [11, 13]. The potential benefits of the PCSK9 inhibitors may include augmentation of endothelial dysfunction and improvement of cellular antiviral defense [14]. However, the proposed clinical benefits of the intensification of lipid-lowering therapies with PCSK9 inhibitors should be tested in randomized and controlled trials in hospitalized COVID-19 patients with and without FH.We have earlier introduced the concept of a “rescue” therapy with PCSK9 inhibitors for middle-aged patients having their FH diagnosis at the age of 40 years or older [15]. Albeit COVID-19 likely poses also a longer term atherothrombotic threat for the high-risk patients with FH, for cost reasons this treatment could only be temporary. However, we can conclude that an intensified treatment of hypercholesterolemia in older patients with FH having COVID-19 needs special attention. Thus, in addition to antecedent statin administration, at least a temporary intensification of LDL-C lowering with a PCSK9 inhibitor should be considered when the diagnosis of the viral disease is made in a patient belonging to this high-risk older patient population.Dr. Vuorio reports no conflicts of interest. Prof. Kovanen has received consultancy fees, lecture honoraria, and/or travel fees from Amgen, Novartis, Raisio Group, and Sanofi. Prof. Strandberg has had educational, consultative, and research collaboration with several companies (incl. Amgen, Merck, OrionPharma, Sankyo, Servier, and Sanofi) marketing cholesterol-lowering drugs.The authors did not receive any funding.All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication." @default.
• W3139328938 created "2021-03-29" @default.
• W3139328938 creator A5034334081 @default.
• W3139328938 creator A5085702429 @default.
• W3139328938 creator A5085875890 @default.
• W3139328938 date "2021-01-01" @default.
• W3139328938 modified "2023-10-06" @default.
• W3139328938 title "Older Familial Hypercholesterolemia Patients with COVID-19" @default.
• W3139328938 cites W2497026247 @default.
• W3139328938 cites W2756164819 @default.
• W3139328938 cites W2995591678 @default.
• W3139328938 cites W3014973984 @default.
• W3139328938 cites W3034592835 @default.
• W3139328938 cites W3048226591 @default.
• W3139328938 cites W3048853848 @default.
• W3139328938 cites W3086590814 @default.
• W3139328938 cites W3109452639 @default.
• W3139328938 cites W3183857127 @default.
• W3139328938 doi "https://doi.org/10.1159/000514447" @default.
• W3139328938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33735871" @default.
• W3139328938 hasPublicationYear "2021" @default.
• W3139328938 type Work @default.
• W3139328938 sameAs 3139328938 @default.
• W3139328938 citedByCount "3" @default.
• W3139328938 countsByYear W31393289382021 @default.
• W3139328938 crossrefType "journal-article" @default.
• W3139328938 hasAuthorship W3139328938A5034334081 @default.
• W3139328938 hasAuthorship W3139328938A5085702429 @default.
• W3139328938 hasAuthorship W3139328938A5085875890 @default.
• W3139328938 hasBestOaLocation W31393289381 @default.
• W3139328938 hasConcept C126322002 @default.
• W3139328938 hasConcept C133925201 @default.
• W3139328938 hasConcept C187212893 @default.
• W3139328938 hasConcept C2776839432 @default.
• W3139328938 hasConcept C2778163477 @default.
• W3139328938 hasConcept C2779120738 @default.
• W3139328938 hasConcept C2908647359 @default.
• W3139328938 hasConcept C71924100 @default.
• W3139328938 hasConcept C99454951 @default.
• W3139328938 hasConceptScore W3139328938C126322002 @default.
• W3139328938 hasConceptScore W3139328938C133925201 @default.
• W3139328938 hasConceptScore W3139328938C187212893 @default.
• W3139328938 hasConceptScore W3139328938C2776839432 @default.
• W3139328938 hasConceptScore W3139328938C2778163477 @default.
• W3139328938 hasConceptScore W3139328938C2779120738 @default.
• W3139328938 hasConceptScore W3139328938C2908647359 @default.
• W3139328938 hasConceptScore W3139328938C71924100 @default.
• W3139328938 hasConceptScore W3139328938C99454951 @default.
• W3139328938 hasIssue "5" @default.
• W3139328938 hasLocation W31393289381 @default.
• W3139328938 hasLocation W31393289382 @default.
• W3139328938 hasOpenAccess W3139328938 @default.
• W3139328938 hasPrimaryLocation W31393289381 @default.
• W3139328938 hasRelatedWork W3205429433 @default.
• W3139328938 hasRelatedWork W4212851988 @default.
• W3139328938 hasRelatedWork W4236030872 @default.
• W3139328938 hasRelatedWork W4256434345 @default.
• W3139328938 hasRelatedWork W4293585201 @default.
• W3139328938 hasRelatedWork W4377221507 @default.
• W3139328938 hasRelatedWork W4386242974 @default.
• W3139328938 hasRelatedWork W193237556 @default.
• W3139328938 hasRelatedWork W2589088314 @default.
• W3139328938 hasRelatedWork W3025721708 @default.
• W3139328938 hasVolume "67" @default.
• W3139328938 isParatext "false" @default.
• W3139328938 isRetracted "false" @default.
• W3139328938 magId "3139328938" @default.
• W3139328938 workType "article" @default.